0001266806 2024-01-01 2024-12-31 0001266806 eyes:Peo1Member 2024-01-01 2024-12-31 0001266806 eyes:Peo2Member 2024-01-01 2024-12-31 0001266806 eyes:Peo1Member 2023-01-01 2023-12-31 0001266806 eyes:Peo2Member 2023-01-01 2023-12-31 0001266806 2023-01-01 2023-12-31 0001266806 eyes:Peo1Member 2022-01-01 2022-12-31 0001266806 eyes:Peo2Member 2022-01-01 2022-12-31 0001266806 2022-01-01 2022-12-31 0001266806 ecd:PeoMember eyes:AdamMendelsohnMember 2024-01-01 2024-12-31 0001266806 ecd:PeoMember eyes:AdamMendelsohnMember 2023-01-01 2023-12-31 0001266806 ecd:PeoMember eyes:MergerScottDunbarMember 2022-01-01 2022-12-31 0001266806 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001266806 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2024-01-01 2024-12-31 0001266806 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember 2024-01-01 2024-12-31 0001266806 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001266806 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001266806 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001266806 ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001266806 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001266806 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001266806 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001266806 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001266806 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001266806 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001266806 ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 iso4217:USD shares iso4217:USD shares pure false 0001266806 DEFR14A VIVANI MEDICAL, INC. true Though we do not have a formal policy regarding the granting practices of our equity awards, we generally approve annual equity grants for executives and the CEO in May, and for other existing employees in the third quarter following the performance appraisal cycle. Each new hire employee is granted stock options that are generally approved at the first quarterly Compensation Committee meeting following their date of hire. Promotions may occur anytime during the year, at which time grants may be awarded and approved at the next scheduled quarterly Compensation Committee meeting. Annual awards to members of our board of directors will be made on the date of our annual meeting of stockholders and initial grants to members of our board of directors are made upon their election or appointment to our Board, as applicable. Our Board and Compensation Committee, as applicable, carefully review any potential material non-public information before granting equity awards. We do not time our equity award grants either to take advantage of a depressed stock price, or an anticipated increase in stock price, and we have limited the amount of discretion that can be exercised in connection with the timing of equity award grants. We also do not time the release of material non-public information based on equity award grant dates or for the purpose of affecting the value of executive compensation. During 2024, we granted stock options to our named executive officers during the period beginning four business days before the filing of a Form 10-Q. These grants were approved at a regularly scheduled meeting of our Compensation Committee occurring in May, pursuant to our typical annual refresh process for executives. false We do not time our equity award grants either to take advantage of a depressed stock price, or an anticipated increase in stock price, and we have limited the amount of discretion that can be exercised in connection with the timing of equity award grants. false Pay Versus Performance As required by Item 402(v) of Regulation S-K, we are providing information about the relationship between executive compensation actually paid (as calculated in accordance with Item 402(v) of Regulation S-K) to our Principal Executive Officer(s) (PEO(s)), and on an average basis, our other Non-Executive Officers (NEOs) or non-PEO NEOs in each case, as determined under SEC rules and certain financial performance measures. The following table shows the total compensation for our PEO(s) and non-PEO NEOs for the fiscal years 2022 through 2024 as set forth in the Summary Compensation Table, the “compensation actually paid” to our PEO(s), and on an average basis, our other non-PEO NEOs (in each case, as determined under SEC rules), our TSR and our net income. <table cellpadding="0" cellspacing="0" id="xdx_301_zkFIvkE47pid" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: center">Fiscal Year</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Summary Compensation Table Total for PEO 1 (Dunbar) 1, 3</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Compensation Actually Paid to PEO 1 (Dunbar)4</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Summary Compensation Total for PEO 2 (Mendelsohn) 1, 3</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Compensation Actually Paid to PEO 2 (Mendelsohn) 5</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Average Summary Compensation Table Total for non-PEO NEOs 2,3</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Average Compensation Actually Paid to non-PEO NEOs5</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Value of Initial Fixed $100 Investment Based on Total Shareholder Return6</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net Income</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 11%; text-align: center">2024</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eecd--PeoTotalCompAmt_d0_c20240101__20241231__ecd--IndividualAxis__custom--Peo1Member_fMSAz_z1DXriqzQQQc" style="width: 8%; text-align: right">0</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eecd--PeoActuallyPaidCompAmt_d0_c20240101__20241231__ecd--IndividualAxis__custom--Peo1Member_fNA_____zJtgYmvfUz9l" style="width: 8%; text-align: right">0</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eecd--PeoTotalCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--Peo2Member_fMw_____z6LdjKIpiZcf" style="width: 8%; text-align: right">1,084,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eecd--PeoActuallyPaidCompAmt_c20240101__20241231__ecd--IndividualAxis__custom--Peo2Member_fMg_____zTc9iDIY044b" style="width: 8%; text-align: right">915,162</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_fMiAz_znjrPDNpLA29" style="width: 8%; text-align: right">770,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_fNQ_____zG0OcaVRzXjc" style="width: 8%; text-align: right">686,961</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eecd--TotalShareholderRtnAmt_pp2d_c20240101__20241231_fNg_____zrGEosBLW6j2" style="width: 8%; text-align: right">28.02</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">($</td><td id="xdx_98A_eus-gaap--NetIncomeLoss_uUSD_c20240101__20241231_zAyc79w2h1Y1" style="width: 8%; text-align: right">23,486,000</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">2023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eecd--PeoTotalCompAmt_d0_c20230101__20231231__ecd--IndividualAxis__custom--Peo1Member_fMSAz_zdOSSZbDohC5" style="text-align: right">0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eecd--PeoActuallyPaidCompAmt_d0_c20230101__20231231__ecd--IndividualAxis__custom--Peo1Member_fNA_____zJsxPD3MAA79" style="text-align: right">0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eecd--PeoTotalCompAmt_c20230101__20231231__ecd--IndividualAxis__custom--Peo2Member_fMw_____ztNb9KgS5Kpi" style="text-align: right">1,044,621</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eecd--PeoActuallyPaidCompAmt_c20230101__20231231__ecd--IndividualAxis__custom--Peo2Member_fMg_____zKLAHeZBs6k" style="text-align: right">954,818</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_fMiAz_zvAv7QQTgGdf" style="text-align: right">693,517</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_fNQ_____zpV39h0LTmf5" style="text-align: right">676,591</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eecd--TotalShareholderRtnAmt_pp2d_c20230101__20231231_fNg_____zbGvXIHjKVch" style="text-align: right">24.64</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">($</td><td id="xdx_98A_eus-gaap--NetIncomeLoss_uUSD_c20230101__20231231_zo2vGhaY65jd" style="text-align: right">25,652,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">2022</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eecd--PeoTotalCompAmt_c20220101__20221231__ecd--IndividualAxis__custom--Peo1Member_fMSAz_zOX7pdY8aTq8" style="text-align: right">382,153</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eecd--PeoActuallyPaidCompAmt_c20220101__20221231__ecd--IndividualAxis__custom--Peo1Member_fNA_____zvSzpfaDLgGi" style="text-align: right">379,269</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eecd--PeoTotalCompAmt_c20220101__20221231__ecd--IndividualAxis__custom--Peo2Member_fMw_____zRshMWikTeki" style="text-align: right">312,014</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eecd--PeoActuallyPaidCompAmt_c20220101__20221231__ecd--IndividualAxis__custom--Peo2Member_fMg_____zTMUkHKJm9m3" style="text-align: right">292,957</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_fMiAz_z5vQma6PPk8l" style="text-align: right">321,605</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_fNQ_____zmNCtoprY4lf" style="text-align: right">70,736</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eecd--TotalShareholderRtnAmt_pp2d_c20220101__20221231_fNg_____zNWtAmt2fE3c" style="text-align: right">20.52</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">($</td><td id="xdx_98C_eus-gaap--NetIncomeLoss_uUSD_c20220101__20221231_z6SYNKbterOk" style="text-align: right">13,889,000</td><td style="text-align: left">)</td></tr> </table> <div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><div style="border-top: Black 1pt solid; font-size: 1pt; width: 10%"> </div></div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="display: none; vertical-align: top; visibility: hidden"> <td style="display: none; width: 0; visibility: hidden"></td><td style="display: none; width: 24pt; visibility: hidden">1.</td><td style="display: none; text-align: justify; visibility: hidden">Adam Mendelsohn served as our PEO for the entirety of fiscal years 2024 and 2023, and for the portion of fiscal year 2022 following our Merger. Scott Dunbar served as PEO in fiscal year 2022 until the Merger.</td></tr> <tr style="display: none; vertical-align: top; visibility: hidden"> <td style="display: none; visibility: hidden"></td><td style="display: none; visibility: hidden">2.</td><td style="display: none; text-align: justify; visibility: hidden">The Company’s non-PEO NEOs (the “Reported NEOs”) for the indicated fiscal years were as follows:</td></tr> <tr style="display: none; vertical-align: top; text-align: justify; visibility: hidden"> <td style="display: none; visibility: hidden"></td><td style="display: none; text-align: left; visibility: hidden">●</td><td style="display: none; text-align: justify; visibility: hidden">2024: Truc Le and Lisa Porter</td> </tr> <tr style="display: none; vertical-align: top; text-align: justify; visibility: hidden"> <td style="display: none; visibility: hidden"></td><td style="display: none; text-align: left; visibility: hidden">●</td><td style="display: none; text-align: justify; visibility: hidden">2023: Truc Le and Lisa Porter</td> </tr> <tr style="display: none; vertical-align: top; text-align: justify; visibility: hidden"> <td style="display: none; visibility: hidden"></td><td style="display: none; text-align: left; visibility: hidden">●</td><td style="display: none; text-align: justify; visibility: hidden">2022: Truc Le and Brigid Makes</td> </tr> <tr style="display: none; vertical-align: top; visibility: hidden"> <td style="display: none; visibility: hidden"></td><td style="display: none; visibility: hidden">3.</td><td style="display: none; text-align: justify; visibility: hidden">Amounts reported in these columns represent (i) the total compensation reported in the Summary Compensation Table for the indicated fiscal year in the case of our PEO(s) and (ii) the average of the total compensation reported in the Summary Compensation Table for the Reported NEOs in the indicated year for such years.</td></tr> <tr style="display: none; vertical-align: top; visibility: hidden"> <td style="display: none; visibility: hidden"></td><td style="display: none; visibility: hidden">4.</td><td style="display: none; text-align: justify; visibility: hidden">Amounts reported in these columns represent the compensation actually paid to our PEO(s) for the indicated fiscal year, as calculated under Item 402(v) of Regulation S-K based on their total compensation reported in the Summary Compensation Table for the indicated fiscal years and adjusted pursuant to Item 402(v) of Regulation S-K. For 2024, the compensation actually paid to Dr. Mendelsohn was based on this total compensation reported in the 2024 Summary Compensation Table and adjusted as shown in the table below:</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="display: none; vertical-align: top; visibility: hidden"> <td style="display: none; width: 0; visibility: hidden"></td><td style="display: none; width: 24pt; visibility: hidden">5.</td><td style="display: none; text-align: justify; visibility: hidden">Amounts reported in this column represent the compensation actually paid to the Reported NEOs in the indicated fiscal year, as calculated under Item 402(v) of Regulation S-K based on the average total compensation for such NEOs reported in the Summary Compensation Table for the indicated fiscal year and adjusted pursuant to Item 402(v) of Regulation S-K. For 2024, the compensation actually paid to the Reported NEOs was based on the average total compensation for such NEOs reported in the 2024 Summary Compensation Table and adjusted as shown in the table below:</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="display: none; vertical-align: top; visibility: hidden"> <td style="display: none; width: 0; visibility: hidden"></td><td style="display: none; width: 24pt; visibility: hidden">6.</td><td style="display: none; text-align: justify; visibility: hidden">Pursuant to Item 402(v) of Regulation S-K, the comparison assumes $100 was invested in our common stock on August 31, 2022 using the closing stock price on that date, the date the combined new entity of Vivani Medical first traded. Historic stock price performance is not necessarily indicative of future stock price performance.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 24pt">1.</td><td style="text-align: justify">Adam Mendelsohn served as our PEO for the entirety of fiscal years 2024 and 2023, and for the portion of fiscal year 2022 following our Merger. Scott Dunbar served as PEO in fiscal year 2022 until the Merger.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 24pt">2.</td><td style="text-align: justify">The Company’s non-PEO NEOs (the “Reported NEOs”) for the indicated fiscal years were as follows:</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 24pt"></td><td style="width: 24pt; text-align: left">●</td><td style="text-align: justify">2024: Truc Le and Lisa Porter</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 24pt"></td><td style="width: 24pt; text-align: left">●</td><td style="text-align: justify">2023: Truc Le and Lisa Porter</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 24pt"></td><td style="width: 24pt; text-align: left">●</td><td style="text-align: justify">2022: Truc Le and Brigid Makes</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 24pt">3.</td><td style="text-align: justify">Amounts reported in these columns represent (i) the total compensation reported in the Summary Compensation Table for the indicated fiscal year in the case of our PEO(s) and (ii) the average of the total compensation reported in the Summary Compensation Table for the Reported NEOs in the indicated year for such years.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 24pt">4.</td><td style="text-align: justify">Amounts reported in these columns represent the compensation actually paid to our PEO(s) for the indicated fiscal year, as calculated under Item 402(v) of Regulation S-K based on their total compensation reported in the Summary Compensation Table for the indicated fiscal years and adjusted pursuant to Item 402(v) of Regulation S-K. For 2024, the compensation actually paid to Dr. Mendelsohn was based on this total compensation reported in the 2024 Summary Compensation Table and adjusted as shown in the table below:</td></tr></table> <table cellpadding="0" cellspacing="0" id="xdx_300_zWReJLThbdck" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">PEO: Adam Mendelsohn</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Fiscal Year</td><td style="font-weight: normal; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: normal; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: normal"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 87%; text-align: left">SCT Total</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eecd--PeoTotalCompAmt_c20240101__20241231_z0fWE6Hezgi1" style="width: 10%; text-align: right">1,084,200</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">- Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year</td><td> </td> <td style="text-align: left">($</td><td id="xdx_981_eecd--AdjToCompAmt_di_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_zuERwOYDkB4l" style="text-align: right">461,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_zVl5gjLIl8Tb" style="text-align: right">281,363</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years</td><td> </td> <td style="text-align: left">($</td><td id="xdx_983_eecd--AdjToCompAmt_di_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_zX149mGSJQvb" style="text-align: right">1,982</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eecd--AdjToCompAmt_d0_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_zJxwBXVmaaMg" style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_z88S8HdSzbM1" style="text-align: right">12,580</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">- Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eecd--AdjToCompAmt_d0_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_zcjbpu8rtst3" style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Dividends and Earnings paid on stock or options in 2024 prior to vesting date</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eecd--AdjToCompAmt_d0_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_zlAXtRyPcgA2" style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left">Compensation Actually Paid</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_zUaDfbY3geAc" style="text-align: right">915,162</td><td style="text-align: left"> </td></tr> </table> Equity award values are calculated in accordance with FASB ASC Topic 718, and the valuation assumptions used to calculate these fair values did not materially differ from those disclosed at the time of grant. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 24pt">5.</td><td style="text-align: justify">Amounts reported in this column represent the compensation actually paid to the Reported NEOs in the indicated fiscal year, as calculated under Item 402(v) of Regulation S-K based on the average total compensation for such NEOs reported in the Summary Compensation Table for the indicated fiscal year and adjusted pursuant to Item 402(v) of Regulation S-K. For 2024, the compensation actually paid to the Reported NEOs was based on the average total compensation for such NEOs reported in the 2024 Summary Compensation Table and adjusted as shown in the table below:</td></tr></table> <table cellpadding="0" cellspacing="0" id="xdx_306_zSVtWMa6PrC7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Fiscal Year</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">AVG REPORTED NEOs 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 87%; text-align: left">SCT Total</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eecd--NonPeoNeoAvgTotalCompAmt_pdp0_c20240101__20241231_zWg4u477j9tl" style="width: 10%; text-align: right">770,400</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">- Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year</td><td> </td> <td style="text-align: left">($</td><td id="xdx_98F_eecd--AdjToCompAmt_di_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_z4RmUu8J3Im9" style="text-align: right">276,600</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_z7GMH7kdIcle" style="text-align: right">168,818</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_zyQUUjwkKPh5" style="text-align: right">5,778</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eecd--AdjToCompAmt_d0_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_fKGkp_ze44zA8CzUgl" style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_fKGkp_zFuJzHFeJILb" style="text-align: right">18,565</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">- Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eecd--AdjToCompAmt_d0_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_zqmQpRrr32Nf" style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Dividends and Earnings paid on stock or options in 2024 prior to vesting date</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eecd--AdjToCompAmt_d0_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_zuDCc0gEwr1" style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left">Compensation Actually Paid</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_985_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_fNA_____zNdD6LWnNE0f" style="font-weight: bold; text-align: right">686,961</td><td style="font-weight: bold; text-align: left"> </td></tr> </table> Please see footnote 1 for the Reported NEOs included in the average for each indicated fiscal year. Equity award values are calculated in accordance with FASB ASC Topic 718, and the valuation assumptions used to calculate these fair values did not materially differ from those disclosed at the time of grant. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 24pt">6.</td><td style="text-align: justify">Pursuant to Item 402(v) of Regulation S-K, the comparison assumes $100 was invested in our common stock on August 31, 2022 using the closing stock price on that date, the date the combined new entity of Vivani Medical first traded. Historic stock price performance is not necessarily indicative of future stock price performance.</td></tr></table> As required by Item 402(v) of Regulation S-K, we are providing information about the relationship between executive compensation actually paid (as calculated in accordance with Item 402(v) of Regulation S-K) to our Principal Executive Officer(s) (PEO(s)), and on an average basis, our other Non-Executive Officers (NEOs) or non-PEO NEOs in each case, as determined under SEC rules and certain financial performance measures. 0 0 1084200 915162 770400 686961 28.02

23486000

0 0 1044621 954818 693517 676591 24.64

25652000

382153 379269 312014 292957 321605 70736 20.52

13889000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 24pt">1.</td><td style="text-align: justify">Adam Mendelsohn served as our PEO for the entirety of fiscal years 2024 and 2023, and for the portion of fiscal year 2022 following our Merger. Scott Dunbar served as PEO in fiscal year 2022 until the Merger.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 24pt">2.</td><td style="text-align: justify">The Company’s non-PEO NEOs (the “Reported NEOs”) for the indicated fiscal years were as follows:</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 24pt"></td><td style="width: 24pt; text-align: left">●</td><td style="text-align: justify">2024: Truc Le and Lisa Porter</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 24pt"></td><td style="width: 24pt; text-align: left">●</td><td style="text-align: justify">2023: Truc Le and Lisa Porter</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 24pt"></td><td style="width: 24pt; text-align: left">●</td><td style="text-align: justify">2022: Truc Le and Brigid Makes</td> </tr></table> Adam Mendelsohn Adam Mendelsohn Merger. Scott Dunbar <table cellpadding="0" cellspacing="0" id="xdx_300_zWReJLThbdck" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">PEO: Adam Mendelsohn</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Fiscal Year</td><td style="font-weight: normal; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: normal; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: normal"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 87%; text-align: left">SCT Total</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eecd--PeoTotalCompAmt_c20240101__20241231_z0fWE6Hezgi1" style="width: 10%; text-align: right">1,084,200</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">- Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year</td><td> </td> <td style="text-align: left">($</td><td id="xdx_981_eecd--AdjToCompAmt_di_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_zuERwOYDkB4l" style="text-align: right">461,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_zVl5gjLIl8Tb" style="text-align: right">281,363</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years</td><td> </td> <td style="text-align: left">($</td><td id="xdx_983_eecd--AdjToCompAmt_di_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_zX149mGSJQvb" style="text-align: right">1,982</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eecd--AdjToCompAmt_d0_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_zJxwBXVmaaMg" style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_z88S8HdSzbM1" style="text-align: right">12,580</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">- Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eecd--AdjToCompAmt_d0_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_zcjbpu8rtst3" style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Dividends and Earnings paid on stock or options in 2024 prior to vesting date</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eecd--AdjToCompAmt_d0_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_zlAXtRyPcgA2" style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left">Compensation Actually Paid</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_zUaDfbY3geAc" style="text-align: right">915,162</td><td style="text-align: left"> </td></tr> </table> 1084200 -461000 281363 -1982 0 12580 0 0 915162 <table cellpadding="0" cellspacing="0" id="xdx_306_zSVtWMa6PrC7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Fiscal Year</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">AVG REPORTED NEOs 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 87%; text-align: left">SCT Total</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eecd--NonPeoNeoAvgTotalCompAmt_pdp0_c20240101__20241231_zWg4u477j9tl" style="width: 10%; text-align: right">770,400</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">- Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year</td><td> </td> <td style="text-align: left">($</td><td id="xdx_98F_eecd--AdjToCompAmt_di_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_z4RmUu8J3Im9" style="text-align: right">276,600</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_z7GMH7kdIcle" style="text-align: right">168,818</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_zyQUUjwkKPh5" style="text-align: right">5,778</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eecd--AdjToCompAmt_d0_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_fKGkp_ze44zA8CzUgl" style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_fKGkp_zFuJzHFeJILb" style="text-align: right">18,565</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">- Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eecd--AdjToCompAmt_d0_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_zqmQpRrr32Nf" style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">+ Dividends and Earnings paid on stock or options in 2024 prior to vesting date</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eecd--AdjToCompAmt_d0_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_zuDCc0gEwr1" style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left">Compensation Actually Paid</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_985_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_fNA_____zNdD6LWnNE0f" style="font-weight: bold; text-align: right">686,961</td><td style="font-weight: bold; text-align: left"> </td></tr> </table> 770400 -276600 168818 5778 0 18565 0 0 686961 <img alt="" src="img001_v1.jpg"/> <img alt="" src="img002_v1.jpg"/> Adam Mendelsohn served as our PEO for the entirety of fiscal years 2024 and 2023, and for the portion of fiscal year 2022 following our Merger. Scott Dunbar served as PEO in fiscal year 2022 until the Merger. Amounts reported in these columns represent (i) the total compensation reported in the Summary Compensation Table for the indicated fiscal year in the case of our PEO(s) and (ii) the average of the total compensation reported in the Summary Compensation Table for the Reported NEOs in the indicated year for such years. The Company’s non-PEO NEOs (the “Reported NEOs”) for the indicated fiscal years were as follows: Amounts reported in these columns represent the compensation actually paid to our PEO(s) for the indicated fiscal year, as calculated under Item 402(v) of Regulation S-K based on their total compensation reported in the Summary Compensation Table for the indicated fiscal years and adjusted pursuant to Item 402(v) of Regulation S-K. For 2024, the compensation actually paid to Dr. Mendelsohn was based on this total compensation reported in the 2024 Summary Compensation Table and adjusted as shown in the table below: Amounts reported in this column represent the compensation actually paid to the Reported NEOs in the indicated fiscal year, as calculated under Item 402(v) of Regulation S-K based on the average total compensation for such NEOs reported in the Summary Compensation Table for the indicated fiscal year and adjusted pursuant to Item 402(v) of Regulation S-K. For 2024, the compensation actually paid to the Reported NEOs was based on the average total compensation for such NEOs reported in the 2024 Summary Compensation Table and adjusted as shown in the table below: Pursuant to Item 402(v) of Regulation S-K, the comparison assumes $100 was invested in our common stock on August 31, 2022 using the closing stock price on that date, the date the combined new entity of Vivani Medical first traded. Historic stock price performance is not necessarily indicative of future stock price performance.